Pelizaeus-Merzbacher disease: on the cusp of myelin medicine

Trends Mol Med. 2024 Apr 5:S1471-4914(24)00060-1. doi: 10.1016/j.molmed.2024.03.005. Online ahead of print.ABSTRACTPelizaeus-Merzbacher disease (PMD) is caused by mutations in the proteolipid protein 1 (PLP1) gene encoding proteolipid protein (PLP). As a major component of myelin, mutated PLP causes progressive neurodegeneration and eventually death due to severe white matter deficits. Medical care has long been limited to symptomatic treatments, but first-in-class PMD therapies with novel mechanisms now stand poised to enter clinical trials. Here, we review PMD disease mechanisms and outline rationale for therapeutic interventions, including PLP1 suppression, cell transplantation, iron chelation, and intracellular stress modulation. We discuss available preclinical data and their implications on clinical development. With several novel treatments on the horizon, PMD is on the precipice of a new era in the diagnosis and treatment of patients suffering from this debilitating disease.PMID:38582621 | DOI:10.1016/j.molmed.2024.03.005
Source: Trends in Molecular Medicine - Category: Molecular Biology Authors: Source Type: research